221 related articles for article (PubMed ID: 20435780)
1. Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae.
Haas W; Pillar CM; Hesje CK; Sanfilippo CM; Morris TW
J Antimicrob Chemother; 2010 Jul; 65(7):1441-7. PubMed ID: 20435780
[TBL] [Abstract][Full Text] [Related]
2. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.
Cambau E; Matrat S; Pan XS; Roth Dit Bettoni R; Corbel C; Aubry A; Lascols C; Driot JY; Fisher LM
J Antimicrob Chemother; 2009 Mar; 63(3):443-50. PubMed ID: 19147516
[TBL] [Abstract][Full Text] [Related]
3. Besifloxacin ophthalmic suspension 0.6%.
Carter NJ; Scott LJ
Drugs; 2010; 70(1):83-97. PubMed ID: 20030427
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro susceptibility of besifloxacin and seven comparators against ciprofloxacin- and methicillin-susceptible/nonsusceptible staphylococci.
Miller D; Chang JS; Flynn HW; Alfonso EC
J Ocul Pharmacol Ther; 2013 Apr; 29(3):339-44. PubMed ID: 23289847
[TBL] [Abstract][Full Text] [Related]
5. Surveillance of the Activity of Aminoglycosides and Fluoroquinolones Against Ophthalmic Pathogens from Europe in 2010-2011.
Sanfilippo CM; Morrissey I; Janes R; Morris TW
Curr Eye Res; 2016 May; 41(5):581-9. PubMed ID: 26200173
[TBL] [Abstract][Full Text] [Related]
6. In vitro time-kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride.
Haas W; Pillar CM; Hesje CK; Sanfilippo CM; Morris TW
J Antimicrob Chemother; 2011 Apr; 66(4):840-4. PubMed ID: 21393192
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children.
Sunakawa K; Farrell DJ
Ann Clin Microbiol Antimicrob; 2007 Aug; 6():7. PubMed ID: 17697316
[TBL] [Abstract][Full Text] [Related]
8. Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile.
Haas W; Gearinger LS; Usner DW; Decory HH; Morris TW
Clin Ophthalmol; 2011; 5():1369-79. PubMed ID: 22034556
[TBL] [Abstract][Full Text] [Related]
9. Besifloxacin ophthalmic suspension for bacterial conjunctivitis.
Nafziger AN; Bertino JS
Drugs Today (Barc); 2009 Aug; 45(8):577-88. PubMed ID: 19927224
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of telithromycin compared with macrolides and fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.
Küçükbasmaci O; Gönüllü N; Aktaş Z; Gürol D; Berkiten R
Int J Antimicrob Agents; 2003 Nov; 22(5):497-501. PubMed ID: 14602368
[TBL] [Abstract][Full Text] [Related]
11. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
Biedenbach DJ; Farrell DJ; Flamm RK; Liverman LC; McIntyre G; Jones RN
Int J Antimicrob Agents; 2012 Apr; 39(4):321-5. PubMed ID: 22306239
[TBL] [Abstract][Full Text] [Related]
12. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
Jones RN; Sader HS; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
[TBL] [Abstract][Full Text] [Related]
13. Activity of garenoxacin, an investigational des-F(6)-quinolone, tested against pathogens from community-acquired respiratory tract infections, including those with elevated or resistant-level fluoroquinolone MIC values.
Jones RN; Fritsche TR; Sader HS; Stilwell MG
Diagn Microbiol Infect Dis; 2007 May; 58(1):9-17. PubMed ID: 17408903
[TBL] [Abstract][Full Text] [Related]
14. Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis.
O'Brien TP
Adv Ther; 2012 Jun; 29(6):473-90. PubMed ID: 22729919
[TBL] [Abstract][Full Text] [Related]
15. Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.
Chang MH; Fung HB
Clin Ther; 2010 Mar; 32(3):454-71. PubMed ID: 20399984
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
Walsh F; Carnegy F; Willcock J; Amyes S
J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against community-acquired bacterial respiratory tract pathogens in the United States: findings from the PROTEKT US study, 2000-2001.
Stratton CW; Brown SD
Clin Ther; 2004 Apr; 26(4):522-30. PubMed ID: 15189749
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase mutations that are associated with high-level resistance to earlier fluoroquinolones in Staphylococcus aureus have less effect on the antibacterial activity of besifloxacin.
Sanfilippo CM; Hesje CK; Haas W; Morris TW
Chemotherapy; 2011; 57(5):363-71. PubMed ID: 21996946
[TBL] [Abstract][Full Text] [Related]
19. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
Haas W; Pillar CM; Zurenko GE; Lee JC; Brunner LS; Morris TW
Antimicrob Agents Chemother; 2009 Aug; 53(8):3552-60. PubMed ID: 19506065
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the effect of bacterial efflux pumps on the antibacterial activity of the novel fluoroquinolone besifloxacin.
Shinabarger DL; Zurenko GE; Hesje CK; Sanfilippo CM; Morris TW; Haas W
J Chemother; 2011 Apr; 23(2):80-6. PubMed ID: 21571623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
